Bronchiolitis obliterans organizing pneumonia (BOOP) is a rare disease, which is histopathologically defined by the presence of granulation tissue in the bronchioles, alveolar ducts and alveoli leading to plugging of the bronchiolar and alveolar lumen. BOOP is considered as a nonspecific response to many types of lung injury, including drugs, radiation, an underlying hematologic malignant neoplasm, autoimmune diseases, bacterial or virus infection, or an underlying lung disease, or occurs idiopathically. BOOP is mainly treated with corticosteroids, which induce a rapid clinical improvement. A frequent problem is relapse of disease when corticosteroid dosage is tapered off. We present the case of a 20-year-old patient with Hodgkin’s disease developing BOOP after chemotherapy (COPP/ABVD) and irradiation. Initially, she responded well to corticosteroids, but relapsed when medication was discontinued. Complete remission of BOOP was achieved by long-term treatment with low-dose methotrexate (5–20 mg/week, i.v.).

1.
Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA: Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985;312:152–158.
2.
Lohr RH, Boland BJ, Douglas WW, Dockrell DH, Colby TV, Swensen SJ, Wollan PC, Silverstein MD: Organizing pneumonia. Features and prognosis of cryptogenic, secondary and focal variants. Arch Intern Med 1997;157:1323–1329.
3.
Gammon RB, Bridges TA, Al-Nezir H, Alexander CB, Kennedy JI: Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematodes. Chest 1992;102:1171–1174.
4.
Davison AG, Heard BE, McAllister WAC, Turner-Warwick MEH: Cryptogenic organising pneumonitis. Q J Med 1983;52:382–394.
5.
Boon ES, Graal MB, van-Noord JA: Primary extranodal non-Hodgkin’s lymphoma of the lung presenting with bilateral, patchy infiltrates dramatically improving after corticosteroid therapy. Chest 1993;104:1292–1293.
6.
Nagai S, Aung H, Tanaka S, Satake N, Mio T, Kawatani A, Kusume K, Kitaichi M, Izumi T: Bronchoalveolar lavage cell findings in patients with BOOP and related diseases. Chest 1992;102(suppl):32s–37s.
7.
Alasaly K, Muller N, Ostrow DN, Champion P, Fitzgerald JM: Cryptogenic organizing pneumonia. A report of 25 cases and a review of the literature. Medicine 1995;74:201–211.
8.
Flowers JR, Clunie G, Burke M, Constant O: Bronchiolitis obliterans organizing pneumonia: The clinical and radiological features of seven cases and a review of the literature. Clin Radiol 1992;45:371–377.
9.
Pommepuy I, Farny M, Billey T, Olivier P, Lassoued S: Bronchiolitis obliterans organizing pneumonia in patient with rheumatoid arthritis. Rev Rheum Engl Ed 1998;65:65–67.
10.
Purcell IF, Bourke SJ, Marshall SM: Cyclophosphamide in severe steroid-resistant bronchiolitis obliterans organizing pneumonia. Respir Med 1997;91:175–177.
11.
Hsue YT, Paulus HE, Coulson WF: Bronchiolitis obliterans in organizing pneumonia in polymyositis. A case report with longterm survival. J Rheumatol 1993;20:877–879.
12.
Ichikawa Y, Ninomiya H, Katsuki M, Hotta M, Tanaka M, Oizumi K: Low-dose/long-term erythromycin for treatment of bronchiolitis obliterans organizing pneumonia (BOOP). Kurume Med J 1993;40:65–67.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.